SOMATROP

Growth Hormone for Recovery & Physical Performance

SOMATROP is a pharmaceutical-grade recombinant human growth hormone developed in the United States for professional medical and scientific use. It is selected by athletes and active individuals for whom recovery, endurance, and physical performance quality are critically important.

When SOMATROP is selected:

• During periods of intensive training and increased physical load

• Throughout recovery following injury, surgery, or physical exhaustion

• In cases of reduced regenerative capacity

• To support lean muscle mass and overall physical condition

Potential effects under medical supervision:

• Support of tissue and muscle recovery processes

• Involvement in protein and lipid metabolism regulation

• Contribution to the preservation of lean muscle mass

• Participation in the development of physical endurance

• Influence on recovery quality following physical exertion

Pharmaceutical quality:

• Recombinant somatropin identical to endogenous human growth hormone

• High degree of purification

• Stable lyophilized formulation

• Manufactured in compliance with GMP and FDA standards

Dosage form:

Lyophilized white or off-white powder for preparation of a solution for injection.

After reconstitution, a clear, colorless solution free of visible particles is obtained.

Packaging: 10 vials × 3.33 mg (10 IU each) — total 100 IU.

Storage conditions:

After reconstitution, store refrigerated at 2–8°C (36–46°F) and use within 30 days.

Do not freeze.

Administration:

Reconstitution: Add 1.0 mL of bacteriostatic water → final concentration 3.3 mg/mL (3300 mcg/mL).

Daily range: 150–500 mcg (conservative replacement protocols), up to 1000–2000 mcg (extended metabolic research protocols).

Measurement reference: At 3.3 mg/mL, 1 unit (0.01 mL) ≈ 33 mcg using a U-100 insulin syringe.

Dosage & Titration:

Recommended gradual weekly dose-adjustment approach:

Initiation: 660 mcg daily.

Conservative target dose: 660–990 mcg daily during the first 2–6 weeks.

Extended target dose: 1320–1650 mcg daily during weeks 7–13+ (metabolic/performance research protocol).

Frequency: Once daily (subcutaneous injection).

Course duration: Typically 12–24 weeks; may extend up to 48 weeks under appropriate medical monitoring.

Timing: Preferably administered in the evening or before bedtime; injection sites should be rotated systematically.

Laboratory Verification:

Certificate of Analysis (CoA):

Manufacturer:

American Pharmaceutical, Inc.

Ohio, USA